Matthew Cooper & Lorenz M. Mayr 
Label-Free Technologies For Drug Discovery 

Over the past two decades the benefits of label-free biosensor
analysis have begun to make an impact in the market, and systems
are beginning to be used as mainstream research tools in many drug
discovery laboratories.

Label-Free Technologies For Drug Discovery summarises the
latest and emerging developments in label-free detection systems,
their underlying technology principles and end-user case studies
that reveal the power and limitations of label-free in all areas of
drug discovery.

Label-free technologies discussed include SPR, NMR,
high-throughput mass spectrometry, resonant waveguide plate-based
screening, transmitted-light imaging, isothermal titration
calorimetry, optical and impedance cell-based assays and other
biophysical methods. The technologies are discussed in relation to
their use as screening technologies, high-content technologies, hit
finding and hit validation strategies, mode of action and ADME/T,
access to difficult target classes, cell-based receptor/ligand
interactions particularly orphan receptors, and antibody and small
molecule affinity and kinetic analysis.

Label-Free Technologies For Drug Discovery is an
essential guide to this emerging class of tools for researchers in
drug discovery and development, particularly high-throughput
screening and compound profiling teams, medicinal chemists,
structural biologists, assay developers, ADME/T specialists, and
others interested in biomolecular interaction analysis.

About the author

Dr Matthew Cooper, Institute for Molecular Bioscience, University of Queensland, Australia
Dr Cooper is a scientist and entrepreneur. He is Co-Founder and Chief Scientific Officer of Akubio Ltd; and Founder and Managing Director of Cambridge Medical Innovations. He has written more than 60 publications and invited reviews in leading scientific journals including Nature Biotechnology, Nature Cell Biology, and Nature Drug Discovery.

Dr Lorenz M. Mayr, Biology Unit, Protease Platform, Novartis Pharma AG, Basel, Switzerland
Dr Mayer is Head of the Biology Unit at the Protease Platform, Centre of Proteomic Chemistry (CPC), at Novartis Pharma AG with responsibility for target finding and target validation, protein expression, assay development and compound screening and profiling for all protease projects. Dr. Mayr is a member of several editorial and scientific advisory boards and also serves as a member at the Board of Directors of SBS, the Society of Biomolecular Sciences.